Study on optimizing linelamine administration scheme for neonatal sepsis based on physiological pharmacokinetics

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063104

Enrollment

Unknown

Registered

2022-08-30

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal infection

Interventions

observation group:Determination of serum linezolid and metabolite concentrations

control group:During the treatment, linelimide is only used in accordance with the prescribed dosage, the concentration of linelimide and its metabolites are not detected, and the dose is not adjusted

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Gestational age <42 weeks, age of admission <28 days, sepsis in accordance with the diagnostic criteria in the Expert Consensus on the Diagnosis and Treatment of Neonatal Sepsis 2019 Edition; 2. Confirmed by blood culture infection were gram positive coccus and USES the rina Cuo amine treatment; 3. Informed consent of family members.

Exclusion criteria

Exclusion criteria: Neonates with congenital malformations, genetic metabolic diseases and immune deficiency diseases.

Design outcomes

Primary

Measure	Time frame
serum linezolid and metabolite concentrations;	—

Countries

China

Contacts

Public ContactFeng Zongtai

nanyifzt@126.com+86 15862440986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026